Guided Therapeutics

Guided Therapeutics R&D per Employee

The R&D Spending per Employee of Guided Therapeutics (GTHP) as of Nov 2, 2026 is 78,166.67 USD. In the previous year, R&D Spending per Employee was 87,666.67 USD — a change of -10.84% (lower).

R&D per Employee

78,166.67USD

YoY

-10.84%

Last updated:

R&D Spending per Employee of Guided Therapeutics is 2025 78,166.67 USD. R&D Spending per Employee of Guided Therapeutics was 2024 87,666.67 USD. It decreases by -10.84% lower compared to the previous year.

The Guided Therapeutics R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
40,666.67 USD
Jan 1, 2019
20,333.33 USD
Jan 1, 2020
23,833.33 USD
Jan 1, 2021
11,500.00 USD
Jan 1, 2022
12,833.33 USD
Jan 1, 2023
38,000.00 USD
Jan 1, 2024
87,666.67 USD
Jan 1, 2025
78,166.67 USD
The Guided Therapeutics R&D per Employee history
YEARR&D per EmployeeYoY
78,166.67USD-10.84%
87,666.67USD+130.70%
38,000.00USD+196.10%
12,833.33USD+11.59%
11,500.00USD-51.75%
23,833.33USD+17.21%
20,333.33USD-50.00%
40,666.67USD-26.95%
55,666.67USD-54.25%
121,666.67USD-50.68%
246,666.67USD-46.95%
465,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Guided Therapeutics Stock analysis

What does Guided Therapeutics do? Guided Therapeutics, Inc. develops medical devices focused on cancer detection using biophotonics. The company's primary product is the LuViva Advanced Cervical Scan, a non-invasive device for cervical cancer screening and triage. LuViva analyzes reflected and fluorescent light after scanning the cervix with light, offering an alternative to conventional tests. The firm targets healthcare providers and clinics seeking point-of-care solutions for cervical cancer detection. LuViva is designed for two main applications: as a screening tool for early detection of cervical cancer and precancers, and as a triage method to reduce unnecessary follow-up procedures. The company focuses on selling and marketing this device to medical facilities, emphasizing its painless, non-invasive nature and point-of-care functionality. Guided Therapeutics conducts limited clinical studies using its biophotonic technology to support the device's efficacy. The business model centers on the commercialization of LuViva, with the company developing prototypes and conducting clinical studies to validate its biophotonic detection method. Guided Therapeutics aims to position LuViva as a standard in cervical cancer screening, targeting healthcare providers who prioritize non-invasive, efficient diagnostic tools. The firm's revenue comes from the sale of LuViva devices and related services to medical institutions. Guided Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Guided Therapeutics stock

R&D Spending per Employee of Guided Therapeutics is 78,166.67 USD in 2025.

R&D Spending per Employee of Guided Therapeutics changed from 87,666.67 USD to 78,166.67 USD, representing a -10.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Guided Therapeutics since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Guided Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Guided Therapeutics

All Key Metrics — Guided Therapeutics